News & Updates

Combining the potent first-in-class capsid assembly inhibitor lenacapavir with other antiretroviral agents led to sustained high rates of virologic suppression in treatment-naïve persons with HIV-1 (PWH) infection, according to the week-54 results of the phase II Calibrate trial.

Ronapreve, also known as REGEN-COV, appears to reduce the risk of hospitalization or the need for additional treatment among COVID-19 patients when used in a real-world setting, a study has shown. The therapy is seen as a promising way to minimize the impact of SARS-CoV-2 infection on the public healthcare system.

Vaccines provide the best defense against COVID-19, but they are not without limitations. Acute infections still occur in some, especially those who are older, smokers, obese, or with type 2 diabetes (T2D), as reported in a study.

Therapy-naïve patients with haematological malignancies are able to mount a stronger immune response to the coronavirus disease 2019 (COVID-19), a recent study has found.

Older patients with COVID-19 may have an increased risk of being hospitalized for acute ischaemic stroke (AIS), particularly in the first 3 days following their COVID-19 diagnosis, according to a study presented at ISC 2022.

In high-risk nonhospitalized patients with mild-to-moderate COVID-19, intramuscular administration of the monoclonal antibody sotrovimab was noninferior to IV infusion of the drug, according to findings from the phase III COMET-TAIL trial presented at CROI 2022.

Results of the Global PERN–COVID-19 study have identified factors that increase the risk of severe outcomes* in children diagnosed with COVID-19.

The coronavirus disease 2019 (COVID-19) pandemic has worsened mental health outcomes among adolescents who care for family members or friends, reports a recent UK study. Psychosocial risk factors before and during the pandemic may explain such burden.